These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9385903)

  • 1. Dose-related hemodynamic and electrocardiographic effects of the calcium promoter BAY y 5959 in the presence or absence of congestive heart failure.
    Rousseau MF; Massart PE; van Eyll C; Etienne J; Ahn S; Schaefer HG; Mueck W; Bornemann M; Pouleur H
    J Am Coll Cardiol; 1997 Dec; 30(7):1751-7. PubMed ID: 9385903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs.
    Yi GH; Burkhoff D; Zhang H; Zhu SM; Zwas D; Wang J
    J Pharmacol Exp Ther; 1998 Aug; 286(2):760-6. PubMed ID: 9694931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of desensitization and enhanced efficiency of calcium channel promoter in conscious dogs with heart failure.
    Asai K; Uechi M; Sato N; Shen W; Meguro T; Mathier MA; Shannon RP; Vatner SF
    Am J Physiol; 1998 Dec; 275(6):H2219-26. PubMed ID: 9843822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
    Stambler BS; Gottlieb SS; Singh BN; Ramanathan KB; Ogilby JD; Ellenbogen KA
    J Am Coll Cardiol; 1995 Dec; 26(7):1679-84. PubMed ID: 7594103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct myocardial effects of OPC-18790 in human heart failure: beneficial effects on contractile and diastolic function demonstrated by intracoronary infusion with pressure-volume analysis.
    MacGowan GA; Haber HL; Cowart TD; Tedesco C; Wu C; Feldman MD
    J Am Coll Cardiol; 1998 May; 31(6):1344-51. PubMed ID: 9581731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction.
    Rousseau MF; Hayashida W; van Eyll C; Hess OM; Benedict CR; Ahn S; Chapelle F; Kobrin I; Pouleur H
    J Am Coll Cardiol; 1996 Oct; 28(4):972-9. PubMed ID: 8837576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
    Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
    J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure.
    Kolseth SM; Wahba A; Kirkeby-Garstad I; Aro S; Nordgaard H; Høydal M; Rognmo Ø; Nordhaug D
    Eur J Cardiothorac Surg; 2012 Jun; 41(6):1377-83. PubMed ID: 22219475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCA50941, a new 1,4-dihydropyridine, reverses endothelin-induced cardiogenic shock in the anesthetized goat.
    Fernández N; García JL; López MG; García AG; Diéguez G
    Life Sci; 1998; 62(21):1933-42. PubMed ID: 9619842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of intravenous butopamine in congestive heart failure.
    Thompson MJ; Huss P; Unverferth DV; Fasola A; Leier CV
    Clin Pharmacol Ther; 1980 Sep; 28(3):324-34. PubMed ID: 7408391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of acute decompensated heart failure with levosimendan].
    Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.
    Monrad ES; McKay RG; Baim DS; Colucci WS; Fifer MA; Heller GV; Royal HD; Grossman W
    Circulation; 1984 Dec; 70(6):1030-7. PubMed ID: 6499142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure.
    Rousseau MF; Massart PE; van Eyll C; Etienne J; Ahn S; Ghadanfar M; Friedrich T; Pouleur H
    Am J Cardiol; 2001 Jun; 87(11):1250-4. PubMed ID: 11377349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
    Colucci WS; Wright RF; Jaski BE; Fifer MA; Braunwald E
    Circulation; 1986 Mar; 73(3 Pt 2):III175-83. PubMed ID: 3510774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure.
    Konstam MA; Cohen SR; Weiland DS; Martin TT; Das D; Isner JM; Salem DN
    Am J Cardiol; 1986 Feb; 57(4):242-8. PubMed ID: 3004184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure.
    Ungar A; Fumagalli S; Marini M; Di Serio C; Tarantini F; Boncinelli L; Baldereschi G; Valoti P; La Cava G; Olianti C; Masotti G; Marchionni N
    Crit Care Med; 2004 May; 32(5):1125-9. PubMed ID: 15190961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.